SCHEMBL24344144

SCHEMBL24344144

CCc1c(C)ccc(Br)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.35
NOS2 P35228 1/20 0.35
HPGD P15428 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB2 P47870 1/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
ALOX15 P16050 1/20 0.33
ALDH1A1 P00352 2/20 0.32
ALOX5 P09917 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
CYP3A4 P08684 1/20 0.31
RECQL P46063 1/20 0.31
ESR1 P03372 1/20 0.30
ESR2 Q92731 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28700541 0.83 NOS2 (0.39) NOS2HPGDTSHRMEN1MAPT
SCHEMBL27488816 0.83 ALDH1A1 (0.37) NOS3NOS2HPGDGABRA1GABRB2
SCHEMBL4135611 0.81 ALDH1A1 (0.43) NOS3NOS2HPGDGABRA1GABRB2
SCHEMBL28141493 0.79 NOS3 (0.39) NOS3NOS2HPGDGABRA1GABRB2
SCHEMBL26339879 0.77 NOS3 (0.38) NOS3NOS2HPGDGABRA1GABRB2
SCHEMBL5195607 0.77 TRPA1 (0.41) NOS3NOS2GABRA1GABRB2ALDH1A1
SCHEMBL23461581 0.77 CYP1A2 (0.35) GABRA1GABRB2
SCHEMBL13057531 0.76 GABRA1 (0.50) NOS3NOS2GABRA1GABRB2GAA
SCHEMBL19003090 0.74 SIRT1 (0.40) NOS3NOS2HPGDGABRA1GABRB2
SCHEMBL19880547 0.74 NOS3 (0.35) NOS3NOS2GABRA1GABRB2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076975-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed